| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Transgenic mice were made by introducing extra copies of the mouse insulin-like growth factor-II (IGF-II) gene driven by the bovine keratin 10 promoter (BKVI). The adult plasma IGF-II levels were elevated at least three times in one line. In this line, there was a lower lipid content of both brown and white adipose depots at 2–4 months of age, and 40% less fat in the carcass at 7–9 months. The low lipid phenotype was not detected in the carcass at 2 weeks after birth. The lean characteristic was attributed to circulating IGF-II because the transgene was not expressed in fat. At 2–4 months of age, the transgenes oxidized more oral lipid, and less of this lipid was incorporated into the whole body and the epididymal fat. In contrast, the interscapular brown adipose tissue maintained lipid incorporation and lipoprotein lipase activity despite its reduced size. The altered activity of the brown adipose tissue may account for the gradual onset and persistence of the lean feature of the transgenic mice. There were no substantial changes in lipogenesis which could account for the low fat content. The plasma levels of IGF-I, insulin, glycerol, non-esterified fatty acids, triacylglycerols and glucose were not greatly changed and the pituitary GH content was within the normal range.
Journal of Endocrinology (1994) 143, 433–439
This article has been cited by other articles:
|
|
 |
|
  J.-P. Therrien, W. Pfutzner, and J. C. Vogel An Approach to Achieve Long-Term Expression in Skin Gene Therapy Toxicol Pathol, January 1, 2008; 36(1): 104 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rodriguez, T. R. Gaunt, S. D. O'Dell, X.-h. Chen, D. Gu, E. Hawe, G. J. Miller, S. E. Humphries, and I. N.M. Day Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits Hum. Mol. Genet., April 1, 2004; 13(7): 715 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Sandhu, J. M. Gibson, A. H. Heald, D. B. Dunger, and N. J. Wareham Low Circulating IGF-II Concentrations Predict Weight Gain and Obesity in Humans Diabetes, June 1, 2003; 52(6): 1403 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Burns and A. B. Hassan Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation Development, October 1, 2001; 128(19): 3819 - 3830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Jones, J. Levorse, and S. M. Tilghman Deletion of a nuclease-sensitive region between the Igf2 and H19 genes leads to Igf2 misregulation and increased adiposity Hum. Mol. Genet., April 1, 2001; 10(8): 807 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Hill, B. Strutt, E. Arany, S. Zaina, S. Coukell, and C. F. Graham Increased and Persistent Circulating Insulin-Like Growth Factor II in Neonatal Transgenic Mice Suppresses Developmental Apoptosis in the Pancreatic Islets Endocrinology, March 1, 2000; 141(3): 1151 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Hassan and J. A. Howell Insulin-like Growth Factor II Supply Modifies Growth of Intestinal Adenoma in ApcMin/+ Mice Cancer Res., February 1, 2000; 60(4): 1070 - 1076. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Zaina and S. Squire The Soluble Type 2 Insulin-like Growth Factor (IGF-II) Receptor Reduces Organ Size by IGF-II-mediated and IGF-II-independent Mechanisms J. Biol. Chem., October 30, 1998; 273(44): 28610 - 28616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, S. Zinkel, K. Polonsky, and E. Fuchs Transgenic studies with a keratin promoter-driven growth hormone transgene: Prospects for gene therapy PNAS, January 7, 1997; 94(1): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
